Nov 06 (Reuters) - Janux Therapeutics Q3 net income USD -24.313 million.
- Q3 collaboration revenue USD 10 million
- Q3 operating expenses USD 45.251 million
- Q3 operating income USD -35.251 million
Nov 06 (Reuters) - Janux Therapeutics Q3 net income USD -24.313 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.